ANNA POTASH: Open Payments
NPI 1598760019 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,551 in 85 payments from 11 companies in 2025. Trend: 2023 $1,680 · 2024 $2,261 · 2025 $2,551
Food & beverage: $2,546Education: $6
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $612 |
| Otsuka America Pharmaceutical, Inc. | 16 | $415 |
| E.R. Squibb & Sons, L.L.C. | 8 | $360 |
| Axsome Therapeutics, Inc. | 8 | $329 |
| Alkermes, Inc. | 8 | $203 |
| ABBVIE INC. | 7 | $197 |
| Neurocrine BioSciences, Inc. | 6 | $172 |
| Teva Pharmaceuticals USA, Inc. | 5 | $149 |
| Almatica Pharma LLC | 2 | $54 |
| Bausch Health US, LLC | 2 | $44 |
Products named: CAPLYTA, REXULTI, COBENFY, Auvelity, LYBALVI, VRAYLAR, INGREZZA, UZEDY.
Industry payments across NY — which companies pay providers there.
